Regeneron Pharmaceuticals has developed and commercialized a broad portfolio of innovative blockbuster biologic medications addressing diverse therapeutic areas, including oncology, immunology, ophthalmology, and rare diseases. Some of its most prominent flagship products include Eylea and Eylea HD for retinal conditions like macular degeneration, Dupixent (developed in collaboration with Sanofi) for eczema, asthma, and chronic rhinosinusitis, Libtayo for advanced cutaneous squamous cell carcinoma and other cancers, Praluent for cholesterol management, and REGEN-COV for viral infections, alongside an expanding pipeline of antibody therapies and novel oncology treatments.